Bio

Erin Grady, MD, CCD, FACNM, FSNMMI is a nuclear medicine physician at Stanford Hospital and Clinics in Stanford, California. She serves as the Interim Division Chief of Nuclear Medicine and Molecular Imaging, Associate Chair of Education and Diversity, Equity and Inclusion, and is program director for the nuclear radiology and nuclear oncology fellowship programs, as well as a coach for the diagnostic radiology program. She is actively involved nationally in the Society of Nuclear Medicine and Molecular Imaging as a Director-at-Large on the SNMMI Board of Directors, and chair of the Government Relations Committee. She serves on the Nuclear Medicine Residency Review Committee for ACGME appeals panel member and assisted with milestone 1.0 development committee for Nuclear Medicine and 2.0 milestone revision committee for Nuclear Radiology at the ACGME. She has been involved in multiple guideline and appropriate use documents on topics related to thyroid cancer (NCCN panel), neuroendocrine tumors, bone scintigraphy, lung scintigraphy and more. In addition, she is a past chair of the American Board of Nuclear Medicine and past president of the American College of Nuclear Medicine. Her areas of research interest include quality, education, radiopharmaceutical therapy and finding answers to clinical questions that arise during the course of practice. She is passionate about education, nuclear medicine’s future, collaboration across specialties, and is a staunch advocate for patients.

Academic Appointments

Honors & Awards

  • Best Clinical Mentor, American College of Nuclear Medicine (2024)
  • Radiology Faculty of the Year, Stanford (2024)
  • Fellow, Society of Nuclear Medicine and Molecular Imaging (2023)
  • Distinguished Service Award, Academic Council of the Society of Nuclear Medicine and Molecular Imaging (2022)
  • Rising Star, Emory Department of Radiology and Imaging Sciences (2020)
  • Fellow, American College of Nuclear Medicine (2015)
  • Rising Star Award, Christiana Care Health System (2015)
  • Robert E. Henkin Government Relations Fellowship, Society of Nuclear Medicine and Molecular Imaging (2012)

Boards, Advisory Committees, Professional Organizations

  • Panel Member - Thyroid Cancer, National Comprehensive Cancer Network (2023 - Present)
  • Board of Directors Member, Intersocietal Accreditation Commission (Nuclear/PET; Therapy) (2021 - Present)
  • Director at Large, Society of Nuclear Medicine and Molecular Imaging (2021 - Present)
  • Board of Directors Member, Education and Research Foundation for Nuclear Medicine and Molecular Imaging (2018 - 2021)
  • Director, Exam Chair, Vice Chair, Chair, Past Chair, American Board of Nuclear Medicine (2014 - 2020)
  • Associate Editor of e-learning for Nuclear Medicine, Vice Chair Nuclear Medicine Radiology Assessment & Review-2, American College of Radiology (2013 - 2016)
  • Director, Newsletter Editor, Annual Meeting Program Chair, Treasurer, Secretary, Vice President Elect, Vice President, President, Past President, American College of Nuclear Medicine (2011 - 2021)

Contact

Additional Info

  • Mail Code: 5281

All Publications

  • Thyroid Carcinoma, Version 1.2025 Featured Updates to the NCCN Guidelines® JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Haddad, R. I., Bischoff, L., Applewhite, M., Bernet, V., Blomain, E., Brito, M., Busaidy, N., Campbell, M., Delozier, O., Duh, Q., Ehya, H., Grady, E., Guo, T., Haymart, M., Hunt, J. P., Kandeel, F., Kotwal, A., Lamonica, D. M., Lorch, J., Mandel, S. J., Markovina, S., Mydlarz, W., Nabell, L., Raeburn, C. D., Rezaee, R., Ridge, J. A., Ritter, H., Roth, M. Y., Salgado, S., Scheri, R. P., Shah, J. P., Sipos, J. A., Sippel, R., Sturgeon, C., Wirth, L. J., Wong, R. J., Worden, F., Yeh, M. W., Darlow, S., Cassara, C. J., Sliker, B. 2025; 23 (7)

    View details for DOI 10.6004/jnccn.2025.0033

    View details for Web of Science ID 001531424600017

    View details for PubMedID 40639400

  • The SNMMI/ACNM Practice Guideline for the Use of Radiopharmaceuticals 5.0 JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY Weatherman, K., Grady, E., Mastascusa, N., Johnson, S., Hinkle, G. H., Laforest, R., Wendorf, C., Thomas, K. S. 2025; 53 (2): 130-134

    View details for Web of Science ID 001509143500008

    View details for PubMedID 40169271

  • Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO oncology practice Perez, K., Del Rivero, J., Kennedy, E. B., Basu, S., Chauhan, A., Connolly, H. M., Dasari, A. N., Gangi, A., Clarke, C. N., Hallet, J., Howe, J. R., Grady, E., Ivanidze, J., Mittra, E. S., White, S. B., Raj, N. P., Vijayvergia, N., Lewis, M. A., Chan, J. A., Kunz, P. L., Mailman, J., Arshad, J., Soares, H. P., Singh, S., Chandrasekharan, C., Soulen, M. C., Janson, E. T., Halfdanarson, T. R., Strosberg, J. R., Bergsland, E. K. 2025: OP2500133

    Abstract

    PURPOSE: To develop a clinical practice guideline and recommendations for symptom management of patients with well-differentiated grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors.METHODS: ASCO convened an Expert Panel to develop a clinical practice guideline by reviewing the literature for relevant guidelines, systematic reviews, randomized controlled trials (RCTs), and observational studies to develop recommendations for clinical practice.RESULTS: The literature review identified eight guidelines, 19 systematic reviews, and three RCTs that informed the development of guideline recommendations.RECOMMENDATIONS: Recommendations are included for carcinoid syndrome, carcinoid heart disease and carcinoid crisis, and functional pancreatic neuroendocrine tumor syndromes. Recommendations are provided for surgical management, liver-directed therapy, and systemic therapy options, as well as palliative care. Limited guidance is provided for sequencing of interventions.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

    View details for DOI 10.1200/OP-25-00133

    View details for PubMedID 40344544

  • The SNMMI/ACNM Practice Guideline for the Use of Radiopharmaceuticals 5.0. Journal of nuclear medicine technology Weatherman, K., Grady, E. E., Mastascusa, N., Johnson, S., Hinkle, G. H., Laforest, R., Wendorf, C., Thomas, K. S. 2025

    View details for DOI 10.2967/jnmt.125.269834

    View details for PubMedID 40169271

  • The Global Reading Room: Performing a Ventilation-Perfusion Study in a Patient With Recent COVID-19. AJR. American journal of roentgenology Grady, E., Pattison, D. A., Redman, S., Satoh, Y. 2024

    View details for DOI 10.2214/AJR.24.31348

    View details for PubMedID 38691414

  • Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Del Rivero, J., Perez, K., Kennedy, E. B., Mittra, E. S., Vijayvergia, N., Arshad, J., Basu, S., Chauhan, A., Dasari, A. N., Bellizzi, A. M., Gangi, A., Grady, E., Howe, J. R., Ivanidze, J., Lewis, M., Mailman, J., Raj, N., Soares, H. P., Soulen, M. C., White, S. B., Chan, J. A., Kunz, P. L., Singh, S., Halfdanarson, T. R., Strosberg, J. R., Bergsland, E. K. 2023: JCO2301529

    Abstract

    PURPOSE: To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.RESULTS: Eight randomized controlled trials met the inclusion criteria for the systematic review.RECOMMENDATIONS: Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)-positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

    View details for DOI 10.1200/JCO.23.01529

    View details for PubMedID 37774329

  • Stronger Together-Collaboration Will Only Enhance Patient Care. Journal of nuclear medicine : official publication, Society of Nuclear Medicine Grady, E. E., Mankoff, D. A., Schuster, D. M. 2023

    View details for DOI 10.2967/jnumed.123.265673

    View details for PubMedID 37562806

  • A Case-Based Primer on FDG PET/CT for Imaging Cardiovascular Infections: Protocol, Interpretation, and Pitfalls. Zhou, W., Moradi, F., Davidzon, G., Song, H., Grady, E., Nguyen, J., Franc, B., Aparici, C., Iagaru, A., Shah, J. SOC NUCLEAR MEDICINE INC. 2023

    View details for Web of Science ID 001109210201036

  • Nuts and Bolts of Ra-223-Dichloride Therapy JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY Grady, E. 2022; 50 (3): 215-221

    Abstract

    Radionuclide therapy with 223Ra-dichloride can be helpful for patients with osteoblastic osseous metastatic disease in the setting of castration resistant prostate cancer without visceral metastases. This article reviews the indications, proper use and handling, patient work-up prior to therapy and many of the technical considerations including discussion of coding/billing along with pitfalls that have been identified.

    View details for DOI 10.2967/jnmt.122.263812

    View details for Web of Science ID 000892612400006

    View details for PubMedID 35882585